PYC would be better off being privately held (in terms of valuation). But that would mean less transparency for minority shareholders.
As long as we keep having this cash runway dangling over our heads, and before any efficacy results are shown, the share price is always going to be under pressure. External validation (partnership/pharma investment) would go a long way but is it worth distracting from the science and the possible dilution?
PYC would be better off being privately held (in terms of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.025(2.17%) |
Mkt cap ! $685.3M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.19 | $1.17 | $5.702K | 4.861K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 549 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 1106 | 3 |
View Market Depth
| Last trade - 10.50am 19/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |